Skip to main content

01.09.2009 | Original Article | Ausgabe 9/2009

Cancer Immunology, Immunotherapy 9/2009

HLA ligand profiles of primary renal cell carcinoma maintained in metastases

Cancer Immunology, Immunotherapy > Ausgabe 9/2009
Juliane Sarah Stickel, Andreas O. Weinzierl, Nina Hillen, Oliver Drews, Mathias M. Schuler, Jörg Hennenlotter, Dorothee Wernet, Claudia A. Müller, Arnulf Stenzl, Hans-Georg Rammensee, Stefan Stevanović
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00262-008-0655-6) contains supplementary material, which is available to authorized users.


In recent years, several approaches have been taken in the peptide-based immunotherapy of metastatic renal cell carcinoma (RCC), although little is known about HLA presentation on metastases compared to primary tumor and normal tissue of RCC. In this study we compared primary tumor, normal tissue and metastases with the aim of identifying similarities and differences between these tissues. We performed this comparison for two RCC patients on the level of the HLA ligandome using mass spectrometry and for three patients on the level of the transcriptome using oligonucleotide microarrays. The quantitative results show that primary tumor is more similar to metastasis than to normal tissue, both on the level of HLA ligand presentation and mRNA. We were able to characterize a total of 142 peptides in the qualitative analysis of HLA-presented peptides. Six of them were significantly overpresented on metastasis, among them a peptide derived from CD151; fourteen were overpresented on both primary tumor and metastasis compared to normal tissue, among them an HLA ligand derived from tumor protein p53. Thus, we could demonstrate that peptide-based immunotherapy might affect tumor as well as metastasis of RCC, but not healthy kidney tissue. Furthermore we were able to identify several peptides derived from tumor-associated antigens that are suitable for vaccination of metastatic RCC.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Weitere Produktempfehlungen anzeigen
Supplementary material 1 (PDF 94 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 9/2009

Cancer Immunology, Immunotherapy 9/2009Zur Ausgabe

Acknowledgement to Reviewers


  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.